European Companies Search Engine

EU funding (€17.8M): Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts Hor 1 Mar 2019 EU Research and Innovation programme "Horizon"

Overview

Text

Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts

IMMUcan proposes an inclusive and integrated European immuno-oncology platform. IMMUcan will access high-quality human biological material (tissue, blood, stool and saliva) and clinical data from patients with colorectal, lung, head & neck, breast, gastric cancers and immune checkpoints inhibitors failures. We have assembled a strong consortium with ten expert clinical centers, access to large volumes of the required tumor types. IMMUcan will mobilize the majority of academic trials running or expected to start recruiting patients during the project period. A centralized workflow for samples, via a state-of-the-art biobank will increase reproducibility as all tissues will be processed and stored in a uniform way, following proofed SOPs. The project will perform in depth immunoprofiling with cutting edge technologies including CyTOFF, single cell RNA-seq, peptidogenomics or microbiome analysis. IMMUcan will analyze the data in order to understand the host/tumour interaction in the absence of treatment (naïve population) and with treatment (patients in follow-up) to identify potential predictive biomarker for response to immunotherapy, or develop rationale for combination therapies. IMMUcan will provide an IT platform and legal/ethical contractual framework where participants from both academia and industry can pursue their own independent investigations utilizing the IMMUcan data and effectively testing and improving the functioning and relevance of the database. A sustainability plan will be developed to ensure the collection of follow-up data and the accessibility of the data platform. The use of the data generating throughout this project, for future research, will be supported.


Funded Companies:

Company name Funding amount
Abbvie Inc. €0.00
Association Hospitaliere de Bruxelles-Centre Hospitalier Universitaire Jules Bordet €350,000
Astrazeneca UK Ltd. €0.00
Bayer AG €0.00
Celsius Therapeutics Inc. €0.00
Centre de Lutte Contre le Cancer Leon Berard €200,000
Centre Hospitalier Universitaire Vaudois €2,202,543
Charite - Universitaetsmedizin Berlin €20,000
Cliniques Universitaires Saint-LUC ASBL €30,000
Consorcio para La Explotacion del Centro Nacional de Analisis Genomico €115,673
De Duve Institute Aisbl €0.00
Eli Lilly and Company Ltd. €0.00
Forum des Patients Europeens €210,000
Fundacio Centre de Regulacio Genomica €138,268
Glaxosmithkline Research & Development Ltd. €0.00
Institut Curie €510,000
Institut de Recherche Pierre Fabre €0.00
Institut de Recherches Internationales Servier €0.00
Institut Gustave Roussy €233,784
Institut National de la Sante et de la Recherche Medicale €448,320
Institut Servier de Medecine Translationnelle €0.00
Janssen Pharmaceutica N.V. €0.00
Katholieke Universiteit Leuven €1,712,880
King's College London €765,066
Ligue Nationale Contre le Cancer €40,780
Luxembourg Institute OF Health €2,807,976
Merck KGaA €0.00
Novigenix SA €0.00
Organisation Europeenne Pour la Recherche et le Traitement du Cancer Aisbl €5,257,790
Owkin France €0.00
Sanofi-Aventis Recherche & Developpement €0.00
SIB Swiss Institute OF Bioinformatics €1,773,000
The University of Birmingham €10,000.00
Universitat Zurich €728,701
Universite Paris Cite €79,220
Uniwersytet Warszawski €95,999
Weizmann Institute OF Science €100,000

Source: https://cordis.europa.eu/project/id/821558

The filing refers to a past date, and does not necessarily reflect the current state.